Position in SCLX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7
-$72 QoQ
Shares Held
1
-94.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#68
of 72 holders
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SCLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026FMR LLC holds $75,393,052,380 across 17 Drug Manufacturers - General names. SCLX ranks #17 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
28,462,475 | $34,138,749,234 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
66,870,816 | $8,448,458,890 | |
| 3 | MRK |
Merck & Co., Inc.
|
45,440,355 | $5,839,085,616 | |
| 4 | JNJ |
Johnson & Johnson
|
22,595,566 | $5,738,595,894 | |
| 5 | AZN |
Astrazeneca PLC
|
28,895,264 | $5,479,119,956 | |
| 6 | ABBV |
AbbVie Inc.
|
20,773,786 | $5,227,515,506 | |
| 7 | BIIB |
Biogen Inc.
|
18,217,239 | $3,936,016,655 | |
| 8 | GSK |
GSK plc
|
64,961,641 | $3,405,289,219 |
All Filings in SCLX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7 | 1 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $79 | 12 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $85 | 7 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $137 | 7 | Shares | Defined | 2025-11-13 | |
| 2025-03-31 | $7,239 | 29,075 | Shares | Defined | 2025-05-12 | |
| 2024-12-31 | $2,075 | 4,874 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $2,074 | 2,244 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $5,589 | 2,896 | Shares | Defined | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||